X

Trial Profile

Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in the Treatment of Intermediate to High Risk Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms NEAR

Most Recent Events

01 Nov 2022 Results of health-related quality of life (HRQoL) during 12 weeks of neoadjuvant apalutamide treatment , published in the International Journal of Urology
26 Jul 2020 Results presented at the 35th Congress of the European Association of Urology
18 May 2020 Results presented at the 115th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com